Oncology Adjuvants Market Report 2026

Oncology Adjuvants Market Overview

• Oncology Adjuvants market size has reached to $1.73 billion in 2025 • Expected to grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: The Increasing Demand For Personalized Medicine Is Fueling The Growth Of The Market Due To Advances In Genetic Profiling, Enabling Tailored And More Effective Oncology Adjuvant Therapies • Market Trend: Development In Immune Checkpoint Inhibitor Adjuvant Therapy Progress in Lung Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oncology Adjuvants Market?

Oncology adjuvants are substances or therapies given alongside primary cancer treatment to enhance effectiveness, reduce side effects, and improve patient outcomes by boosting the immune response, reducing tumor resistance, or aiding in symptom management. These aim to provide a more comprehensive and personalized approach to cancer management. The main types of oncology adjuvants are chemotherapy adjuvants, radiation adjuvants, immunotherapy adjuvants, hormonal adjuvants, and targeted therapy adjuvants. Chemotherapy adjuvants refer to drugs or substances used alongside primary chemotherapy treatments to enhance their effectiveness, reduce side effects, or improve the body’s response to cancer therapy. It is administered through various routes, such as oral, intravenous, subcutaneous, topical, and intramuscular, and is used in several indications, including breast cancer, glioblastoma, lung cancer, colorectal cancer, ovarian cancer, sarcoma, prostate cancer, and others, and caters to several end users, such as cancer research institutes and cancer hospitals.

What Is The Oncology Adjuvants Market Growth Forecast?

The oncology adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of novel immunotherapy adjuvants, expansion of targeted therapy options, increasing adoption of combination therapy approaches, integration of precision medicine and genomic profiling, rising investment in oncology research and clinical trials. Major trends in the forecast period include rising adoption of immunotherapy and targeted therapy adjuvants, increased integration of personalized cancer treatment plans, expansion of oral and subcutaneous administration routes, growth in multi-modal cancer treatment approaches, focus on enhancing patient outcomes and reducing therapy side effects.

Global Oncology Adjuvants Market Segmentation

1) By Type Of Adjuvant: Chemotherapy Adjuvants, Radiation Adjuvants, Immunotherapy Adjuvants, Hormonal Adjuvants, Targeted Therapy Adjuvants 2) By Administration Route: Oral, Intravenous, Subcutaneous, Topical, Intramuscular 3) By Indication: Breast Cancer, Glioblastoma, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Sarcoma, Prostate Cancer, Other Indications 4) By End User: Cancer Research Institute, Cancer Hospitals Subsegments: 1) By Chemotherapy Adjuvants: Alkylating Agents, Antimetabolites, Anthracyclines, Plant Alkaloids, Topoisomerase Inhibitors, Platinum-Based Compounds, Others 2) By Radiation Adjuvants: Radiosensitizers, Radioprotectors, Hypoxic Cell Sensitizers, Deoxyribonucleic Acid (DNA) Repair Inhibitors, Immune Modulating Agents Combined With Radiation 3) By Immunotherapy Adjuvants: Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Transfer, Immune Modulating Agents 4) By Hormonal Adjuvants: Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Gonadotropin-Releasing Hormone Agonists Or Antagonists, Androgen Receptor Inhibitors, Estrogen Receptor Downregulators 5) By Targeted Therapy Adjuvants: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, mTOR Inhibitors, v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors, Vascular Endothelial Growth Factor (VEGF) Inhibitors

What Is The Driver Of The Oncology Adjuvants Market?

The increasing demand for personalized medicine is expected to propel the growth of the oncology adjuvants market going forward. Personalized medicine refers to a medical model that uses information about a person’s genes and lifestyle environment to tailor treatments and healthcare to their specific needs. Personalized medicine is rising due to advancements in genetic and molecular profiling, which enable treatments tailored to an individual’s unique biological makeup, improving effectiveness and reducing adverse effects. Oncology adjuvants help personalized medicine by allowing the customization of additional cancer treatments based on a patient’s unique genetic makeup and tumor characteristics, ensuring that therapies target residual cancer cells effectively while minimizing unnecessary side effects. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, up from 6 in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the oncology adjuvants industry.

Key Players In The Global Oncology Adjuvants Market

Major companies operating in the oncology adjuvants market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Elicio Therapeutics Inc.

Global Oncology Adjuvants Market Trends and Insights

Major companies operating in the oncology adjuvants market are focusing on developing advanced solutions, such as immune checkpoint inhibitor adjuvant therapy to enhance post-surgical treatment efficacy, and improve overall patient survival by harnessing the body’s immune system to target residual tumor cells. Immune checkpoint inhibitor adjuvant therapy refers to the use of drugs that block immune checkpoint proteins such as PD-1, PD-L1, or CTLA-4 that normally act as brakes on the immune system. For instance, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, launched KEYTRUDA (pembrolizumab) as an adjuvant treatment, which received approval from the Food and Drug Administration (FDA). It follows surgical resection and platinum-based chemotherapy for patients with Stage IB (T2a ≥4 centimeters), II, or IIIA non-small cell lung cancer (NSCLC). KEYTRUDA (pembrolizumab) offers targeted immune checkpoint inhibition by blocking the PD-1 receptor, thereby restoring the immune system’s ability to detect and attack cancer cells. It provides an effective adjuvant treatment option for patients with non-small cell lung cancer (NSCLC) following surgery and chemotherapy, helping to reduce the risk of cancer recurrence and improve overall survival. Additionally, KEYTRUDA supports personalized cancer therapy by leveraging the patient’s immune response, making it a vital tool in modern immuno-oncology.

What Are Latest Mergers And Acquisitions In The Oncology Adjuvants Market?

In January 2024, Transgene S.A., a France-based healthcare technology company, partnered with NEC Corporation to advance robotic-assisted medical solutions. With this partnership, Transgene and NEC aim to enhance procedural accuracy, operational efficiency, and patient outcomes by combining Transgene’s therapeutic development expertise with NEC’s AI, 5G, and imaging technologies, while improving workflow integration, supporting real-time clinical decision-making, and enabling broader access to advanced healthcare solutions. NEC Corporation is a Japan-based technology company that specializes in information technology, communications, and AI-driven imaging solutions for healthcare and enterprise applications.

Regional Insights

North America was the largest region in the oncology adjuvants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oncology Adjuvants Market?

The oncology adjuvants market consists of revenues earned by entities by providing services such as treatment enhancement, side effect reduction, tumor resistance prevention, and personalized therapy optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology adjuvants market also includes sales of nutritional adjuvants, gene therapy adjuvants, oncolytic virus adjuvants, and hyperthermia adjuvants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oncology Adjuvants Market Report 2026?

The oncology adjuvants market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oncology adjuvants industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.